Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer.

ABSTRACT:

Importance

Neoadjuvant therapy is increasingly used in localized pancreatic carcinoma, and survival is correlated with carbohydrate antigen 19-9 (CA19-9) levels and histopathologic response following neoadjuvant therapy. With several regimens now available, the choice of chemotherapy could be best dictated by response to neoadjuvant therapy (as measured by CA19-9 levels and/or pathologic response), a strategy defined herein as adaptive dynamic therapy.

Objective

To evaluate the association of adaptive dynamic therapy with oncologic outcomes in patients with surgically resected pancreatic cancer.

Design, setting, and participants

This retrospective cohort study included patients with localized pancreatic cancer who were treated with either gemcitabine/nab-paclitaxel or

SUBMITTER: AlMasri S 

PROVIDER: S-EPMC9227002 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature